The company today announced a strategic partnership with Manhattan Labs, an independent clinical laboratory that serves the New York City area. Its emphasis is on women’s health, particularly obstetrics and reproductive issues. Manhattan labs will market and distribute in New York City CombiMatrix microarray tests for the miscarriage management testing market.
The agreement between the two firms was directly enabled by the announcement in June that CombiMatrix miscarriage management tests had received conditional approval from the New York State Department of Health for testing on patient samples within New York state.
Miscarriage management testing allows OB/GYN doctors to better determine if there is a genetic cause for a miscarriage or other related events. Microarray testing is believed by many in the industry to be the coming standard of care since it can identify a greater number of possible genetic abnormalities more accurately than currently available technology.
The partnership is a key step for CombiMatrix. First, it shows that microarray testing is indeed becoming more and more accepted as a diagnostic tool in the women’s health field. Secondly, it gives the company access into the large New York City market for its leading growth product. For additional information about CombiMatrix and its entire product line, please visit www.combimatrix.com.
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html
